ModuleTitle@CompanyName@Symbol@Address@Phone@Industry@Sector@Region@CompanyDescription@KeyExecutives@Number_of_employees@Subsidiaries
Company Description@Alexion Pharmaceuticals, Inc.@ALXN@121 SEAPORT BOULEVARD, BOSTON, Massachusetts, 02210, Switzerland@4752302596@Major Pharmaceuticals@Health Care@North America@"Alexion is a global biopharmaceutical company focused on serving patients and
families affected by rare diseases through the discovery, development and
commercialization of life-changing therapies.
As the global leader in complement biology and inhibition for more than 20
years, Alexion has developed and commercializes two approved complement
inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and
atypical hemolytic uremic syndrome (aHUS), as well as the first and only
approved complement inhibitor to treat anti-acetylcholine receptor (AChR)
antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica
spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody
positive.&nbsp;&nbsp;... <a href=""http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f04%2f0000899866-20-000012.html#FIS_BUSINESS"" target=""_blank"">More</a> ...&nbsp;&nbsp;
"@[('Aradhana Sarin', 'Chief Financial Officer & Executive Vice President'), ('Brian M. Goff', 'Chief Commercial, Global Operations Officer & EVP'), ('John J. Orloff', 'Executive VP, Head-Research & Development'), ('Ludwig N. Hantson', 'Chief Executive Officer & Director'), ('Paul J. Clancy', 'Chief Financial Officer')]@['2,525']@['NO INFO']
